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Summary 
Insulin-like  growth factor I (IGF-I)/somatomedin C is an important mediator of keratinocyte 
growth in vitro, and the expression of IGF-I receptors in the basal layer of normal epidermis 
suggests  that this growth pathway may function in the regulation of keratinocyte  growth in 
vivo as well. The pattern of IGF-I receptor expression in normal skin is distinct from that of 
the epidermal growth factor (EGF) receptor, suggesting that these receptors might be differentially 
regulated.  The purpose of this study was to obtain a better understanding of IGF-I receptor 
function in the skin by examining IGF-I receptor expression in psoriatic epidermis and in cultured 
human keratinocytes. Our findings indicate that IGF-I receptor expression is increased in psoriasis 
as measured by protein tyrosine kinase assays of biopsy extracts and by immunohistochemical 
staining with an IGF-I receptor-specific monoclonal antibody. Unlike EGF receptor expression, 
which is also increased in psoriatic epidermis, the pattern of IGF-I receptor expression corresponds 
closely with the increased  size of the keratinocyte proliferative  compartment in psoriasis. Biochemical 
agents that diminish EGF receptor ligand binding (phorbol ester or calcium ionophore treatment) 
produce opposite  effects on the IGF-I receptor.  These results suggest  that cellular expression 
and differential regulation of both growth factor receptor  systems may control critical aspects 
of epidermal proliferation  or function. 
I 
nsulin-like  growth factor  I  (IGF-I), 1 previously  termed 
somatomedin C, is a 7.5-kD polypeptide that circulates 
in plasma in high concentrations and is detectable in most 
tissues (1). IGF-I, insulin, and IGF-II comprise a family of 
structurally related hormones that, nonetheless, produce dis- 
tinct metabolic effects through interactions with unique cell 
surface receptors  (2, 3).  IGF-I functions predominantly as 
a mitogenic factor for a variety of cell and tissue types, unlike 
insulin and IGF-II,  which serve predominantly as anabolic 
hormones, regulating glucose and mannose-6-phosphate  in- 
tracellular transport, respectively  (3). The importance of IGF-I 
to growth of postembryonic tissues is suggested by increasing 
plasma concentrations throughout adolescence,  reaching a pla- 
teau in adults,  and in the requirement of most mammalian 
cell types for IGF-I for sustained proliferation  (1). 
The IGF-I receptor is composed of two subunits: c~, a 125- 
1Abbreviations used in  this paper: BB,  binding  buffer;  EGF, epidermal 
growth factor; FGF, fibroblast growth factor; IGF-I, insulin-like growth 
factor I; KBM, keratinocyte  basal medium; KGF, keratinocyte  basal medium. 
kD protein that is entirely extraceUular  and functions in ligand 
binding, and B, a 95-kD transmembrane protein, with ex- 
tracellular and cytoplasmic domains.  The IGF-I receptor is 
synthesized  as  a  single  chain  propeptide  that  undergoes 
glycosylation, proteolytic cleavage, and assembly into a 350- 
kD  heterodimer of both  subunits  (olz82) (4). The IGF-I 
receptor exhibits high affinity for binding of IGF-I, low affinity 
for binding of insulin, and intermediate affinity for binding 
of IGF-II (2). Thus, depending on ligand concentration, each 
of these factors has the potential to activate the IGF-I receptor 
after binding. Mitogenic signaling after ligand binding is pro- 
duced by activation of tyrosine kinase enzymatic activity as- 
sociated with the cytoplasmic portion of the IGF-I receptor 
B subunit.  Although the insulin receptor possesses a struc- 
turally similar tyrosine kinase domain, the mitogenic prop- 
erties of the IGF-I receptor are specific to unique sequences 
in its tyrosine kinase region (5). Like expression of the IGF-I 
ligand, tissue expression of the IGF-I receptor is also develop- 
mentally regulated (6). 
The roles of IGF-I and its receptor in regulation of skin 
structure and function are only partly understood. Epidermal 
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as fibroblasts and vascular elements, express receptors for IGF-I 
(10, 11). In connective tissue cells, such as fibroblasts,  IGF-I 
regulates cell proliferation in conjunction with platelet-derived 
growth factor or other mitogens (12). In keratinocytes,  IGF-I 
regulates proliferation via synergistic interactions with epi- 
dermal growth factor (EGF) or fibroblast growth factor (FGF)- 
like hormones (9, 13). The IGF-I receptor is localized in the 
basal epidermal layer of normal human skin, where it could 
serve to regulate keratinocyte proliferation in conjunction with 
EGF or other mitogens (9). However, the expression  of the 
IGF-I receptor in human epidermis is distinct from that of 
the EGF receptor, which is located in both spinous and basal 
epidermal compartments (9,  14,  15). To better understand 
the regulation and function of the IGF-I receptor in human 
skin, we have studied IGFoI receptor expression in psoriatic 
tissue and in cultured keratinocytes. We report that IGF-I 
receptor expression  is increased in psoriatic epidermis, par- 
alleling the increased size of the epidermal proliferative com- 
partment, and that IGF-I receptor expression is differentially 
regulated in human keratinocytes compared with expression 
of the EGF receptor. 
Materials and Methods 
Reagents.  Reagents were obtained from Sigma Chemical Co. 
(St. Louis, MO), except where noted. 
Receptor  Binding Studies.  Receptor binding assays  were done as 
previously  described (9). Briefly,  cultured human neonatal foreskin 
keratinocytes  were grown in keratinocyte growth medium (KGM; 
Clonetics Corp., San Diego, CA) to ,~75% confluence  in 24-well 
tissue culture plates. For experiments performed in KGM, com- 
pounds were added in KGM for the indicated times and the plates 
were then washed twice for 90 rain at 37~  with keratinocyte  basal 
medium (KBM; Clonetics Corp.) before the assay. For analysis  of 
receptor binding in KBM, plates were transferred  to KBM for 24 h 
before the addition of  compounds  in KBM. Added  compounds  were 
10 ng/ml PMA (LC Services Corp.; Woburn, MA), 10 ng/ml 4a- 
PMA (LC Services Corp.), 1.15 mM CaC12, and the Ca  z+ iono- 
phores ionomycin (1/~M) and A23187 (0.1 #M). Plates  were placed 
on ice and washed once with cold binding buffer (BB: KBM, 5 
mg/ml BSA, 20 mM Hepes, pH 7.3) followed by the addition of 
0.25 ml/well of 12SI-EGF (Amersham Corp., Arlington Heights, 
IL; sp act, 100/~Ci//~g) or nsI-IGF-I (Amersham Corp.; sp act, 
2,000 Ci/mmol) in BB to each well. Plates were transferred to a 
rocking incubator at 4~  for 6 h and then washed four times with 
BB. Cells were lysed in 0.1 M NaOH/0.1% Triton X-100, and 
counts were read in a gamma counter. Nonspecific binding was 
measured with a 5,000-fold excess of unlabeled EGF or IGF-I 
(PeproTech Corp., Rocky Hill, NJ) and did not exceed  20% of total 
binding. Receptor binding inhibition experiments were performed 
as described above with 1 ng/ml 12sI-IGF-I mixed with unlabeled 
IGF-I, insulin (Clonetics Corp.), or mAb c~-IR-3, mAb ce-Ilk-3 
was a generous gift of Dr. Steven  Jacobs (WeUcome  Research Labora- 
tories, Research Triangle Park, NC). Each value represents mean 
specific binding of triplicate measurements. 
Immunohistochemistry.  Immunoperoxidase staining of cryostat 
sections of skin from 18 psoriatic  patients was performed  with mouse 
mAb  ce-IR-3,  as  described previously (9), using  3-amino-9- 
ethylcarbazole as the developing reagent. 
Tyrosine  Kinase Assays.  Split-thickness  skin biopsies from three 
psoriatic patients were homogenized in 0.5 ml of lysis  buffer (LB, 
20 mM Tris, pH 8.0, containing 150 mM NaC1, 10% glycerol, 
1% Triton X-100, I mM PMSF, 0.15 U/ml aprotinin, and 1 mM 
sodium orthovanadate) using a motor-driven Teflon pestle. After 
homogenization, insoluble material was removed by centrifuga- 
tion in a microfuge for 15 min at 4~  Protein concentration was 
determined using the protein assay  kit according to the manufac- 
turer's instructions (Bio-Rad Laboratories, Richmond, CA), and 
60/zg of each protein sample was immunoprecipitated with 1/~1 
ce-IR-3 or 1/~1 rabbit anti-EGF receptor antibody (a generous gift 
of Dr. Stuart Decker, The Rockefeller University) at 4~  over- 
night. Subconfluent  cultured neonatal  keratinocytes  grown in KGM 
were treated for 24 h with KBM before lysis. 30 min before lysis, 
the medium was changed to KBM alone or containing 100 ng/ml 
IGF-I and reincubated at 37~  Cultured keratinocytes were then 
lysed in 1 ml LB/plate, and ~300/~g protein was immunoprecipi- 
tated with 2/~1 ol-IR-3 overnight. For EGF receptor immunopre- 
cipitation from cultured keratinocytes, cells grown in KGM were 
lysed as described above and immunoprecipitated with 1/zl rabbit 
antioEGF receptor at 4~  overnight. Immunoprecipitates  were then 
bound for 4 h to protein A-Sepharose  beads alone (for EGF receptor 
immunoprecipitations) or that had been preincubated with rabbit 
anti-mouse  IgG (Organon  Teknika-Cappel; Malvern, PA). Im- 
munoprecipitates were washed once with cold PBS, twice with 
0.5 M LiC1 in 20 mM Tris, pH 8.0, and once with kinase buffer 
(50  mM  Tris, pH  7.4, 10  mM MnCI2). The  beads were re- 
suspended in 40/~1 kinase buffer and the kinase reaction was al- 
lowed to proceed for 15 min at room temperature after the addi- 
tion  of  1  /~1  7-[32p]ATP (Amersham  Corp.,  sp  act,  6,000 
Ci/mmol). The reaction mixtures were washed twice with 1 ml 
kinase buffer and then boiled 5 min in 50 #12 x SDS sample  buffer. 
Proteins were subjected to electrophoresis in a 7.5% SDS-PAGE 
gel, and gels were fixed,  dried, and exposed at - 70~  using XAR-5 
film (Eastman Kodak Co., Rochester, NY) and Cronex intensifying 
screens (DuPont Co., Wilmington, DE). Gels of psoriatic skin 
sample kinase reactions after  immunoprecipitation  with  EGF 
receptor and IGF-I receptor antibodies were both exposed for 2 d. 
Results 
mAb ~-IR-3 Recognizes the IGF-I Receptor in Human Ker- 
atinocytes.  The mAb o~-IR-3 was raised to IGF-I receptors 
purified from human placental membranes (16). o~-IR-3 reacts 
with an antigenic site on the extracellular ol subunit (16), 
and its specificity has been demonstrated in a variety of cell 
types (16-19). The reactivity of ce-IR-3 with basal keratino- 
cytes in normal human epidermis has been previously reported 
(9). To further substantiate the ability of o~-IR-3 to recog- 
nize the IGF-I receptor in human keratinocytes, radioreceptor 
competition and immunoprecipitation experiments were per- 
formed with cultured normal human keratinocytes. Fig.  1 
displays results obtained with radioreceptor competition ex- 
periments. In these experiments, the ability of IGF-I, insulin, 
and oMR-3 to inhibit binding of t2sI-IGF-I was measured 
on keratinocyte monolayers. Unlabeled IGF-I displaced 90% 
binding of radiolabeled  IGF-I, whereas a 1,000-fold  higher 
insulin concentration only displaced 57% of binding of IGF-I, 
consistent with the lower affinity of insulin for the IGF-I 
receptor and results obtained previously in other cell types 
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Figure 1.  mAb ot-IR-3 inhibits binding of 12sI-IGF-I 
to cultured human keratinocytes. 12sI-IGF-I (1 ng/ml) 
binding was measured  in the presence  of the indicated con- 
centrations of insulin, IGF-I, and a-IP,-3. Data are ex- 
pressed as the percentage of counts bound in the condi- 
tion tested/counts bound in KBM alone. 
(2).  ot-IR-3 displayed an  ability to inhibit  binding  of 125I- 
IGF-I to its receptor to nearly the same extent as IGF-I (Fig. 1). 
The  specificity of ot-IR-3 binding  to the IGF-I receptor 
was also confirmed by immunoprecipitation  of the receptor 
from keratinocyte lysates followed by autophosphorylation 
in an in vitro kinase reaction (Fig. 2). The 95-kD 3  subunit 
of the IGF-I receptor was detected only when cells were briefly 
exposed to IGF-I before immunoprecipitation  (Fig. 2, lanes 
B  and  C). 
Analysis of lGF-I Receptor Expression in Psoriatic  Epidermis 
by Immunohistochemistr  7.  Since activation of the IGF-I receptor 
by IGF-I or supraphysiological insulin concentrations is ob- 
ligate for keratinocyte mitogenic activation by EGF (9, 20) 
or bFGF (20), the expression of the IGF-I receptor may define 
the potential proliferative pool of keratinocytes in epidermal 
tissue (9).  As the proliferative keratinocyte population  ex- 
tends to suprabasal keratinocytes in lesional psoriatic epidermis 
(21),  the expression of IGF-I receptors was compared in le- 
sional  and  nonlesional  psoriatic  epidermis  by  immuno- 
histochemistry  with  the cr-IR-3  antibody.  Biopsy samples 
of active psoriatic plaques and normal-appearing nonlesional 
skin from  18 patients  were sectioned on a cryostat micro- 
tome and were reacted with ot-IR-3 antibody.  Representa- 
tive results from this analysis are shown in Fig. 3. In normal 
human  epidermis,  plasma  membrane  staining  by  ot-IR-3 
(which  presumably  represents  receptors  capable of ligand 
binding or activation) is confined to basal keratinocytes (9). 
In contrast, acanthotic epidermis from lesional psoriatic plaques 
shows plasma membrane staining with ot-IR-3 in both basal 
keratinocytes and in lower spinous keratinocytes (Fig. 3, B-D), 
corresponding to the increased proliferative keratinocyte com- 
partment  in lesional psoriatic epidermis  (21).  Biopsy tissue 
from 18 individuals with active psoriatic lesions consistently 
showed this pattern of IGF-I receptor staining at cell surfaces 
of basal and lower spinous epidermal  layers.  Diffuse, cyto- 
plasmic staining was variably seen in mid and upper spinous 
keratinocyte layers. IGF-I receptor expression was also studied 
in normal appearing,  nonlesional  skin from 15 of these pa- 
tients with  active psoriatic lesions (Fig.  3 A).  Cell surface 
IGF-I receptor expression in  13 of 15 tissue samples (87%) 
Figure 2.  mAb ot-IR-3 immuno- 
precipitates the IGF-I receptor  in cul- 
tured human keratinocytes.  Cells  were 
grown in basal medium for 24 h be- 
fore lysis, and the sample in lane C 
was treated  with 100 ng/ml IGF-I  for 
the last 30 min. Cell lysates  were  im- 
munoprecipitated  with ,x-IR-3 (lanes 
B and C) or an isotypic  control anti- 
body (lane A) and then autophos- 
phorylated by an in vitro kinase assay 
in the presence of 3~-[32p]ATP. The 
arrow indicates the 95-kD 18 subunit 
of the IGF-I receptor. 
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with skin from normal individuals (9). Diffuse, cytoplasmic 
staining of IGF-I receptors  was also seen in some suprabasal 
keratinocytes. Two other samples of nonlesional skin from 
psoriatics showed focal areas of suprabasal membrane staining 
for the IGF-I receptor in addition to basal  staining. 
Analysis of lGF-I Receptor Expression in Psoriatic  Epidermis 
by Immunoprecipitation  and Kinase  Assay.  To confirm the ap- 
parent  increase  in  IGF-I  receptor  expression  in  psoriatic 
epidermis, IGF-I receptor kinase activity was assessed in psori- 
atic tissue. Split-thickness biopsies consisting predominantly 
of epidermal tissue were obtained from lesional and nonle- 
sional skin from three different individuals. Equal quantities 
of homogenized tissue protein were immunoprecipitated with 
c~-IR-3, and receptor autophosphorylation was then initiated 
by the addition of 3~-[32p]ATP. Kinase reaction samples were 
separated by SDS-PAGE with the results shown in Fig. 4 a. 
In all three paired samples, IGF-I receptor kinase activity as 
Figure 3.  Immunohistochemical  reactivity  of psoriatic epidermis with the anti-lGF-I receptor mAb, ~-IR-3. Intense  membrane staining (arrows) 
of both basal and suprabasal keratinocytes  is observed in psoriatic lesional  epidermis (B-D), while  plasma membrane  reactivity  is confined  to the basal 
layer of keratinocytes  in normal appearing, nonlesional  skin (A). Weaker  cytoplasmic  staining  of spinous keratinocytes  with the mAb is also detected 
as indicated  by the open arrowheads. 
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in psoriatic epidermis. Paired  immunoprecipitation and 
kinase reactions on tissue extracts were performed with 
IGF-I receptor antibody a-IR-3 (a) or an EGF receptor 
antibody (b). Samples used for immunoprecipitation 
consisted of 60/~g of protein from nonlesional (lanes 
A, C, and E) and lesional (lanes B, D, and F) split- 
thickness biopsies of  patients 1 (lanes  A and B), 2 (lanes 
C  and D), and 3 (lanes E  and F).  (b) Lane G is an 
immunoprecipitation of proteins from cultured human 
keratinocytes  with the EGF receptor antibody as a posi- 
tive control. After immunoprecipitation, samples  were 
then autophosphorylated  with 3,[32P]. The arrow in 
a indicates the 95-kD B subunit of the IGF-I receptor, 
while the arrow in b denotes the 170-kD EGF receptor. 
measured by receptor autophosphorylation was greater in 
psoriatic tissue than in the paired nonlesional specimen. Den- 
sitometry measurements showed a 5-20-fold increase in ki- 
nase activity in psoriatic epidermis compared with paired non- 
lesional  specimens.  In  contrast  with  the  kinase assay on 
cultured keratinocytes in Fig. 2, IGF-I receptor kinase activity 
is detectable in psoriatic tissue without the addition of exog- 
enous IGF-I (despite the use of approximately fivefold less 
total protein from the biopsy samples than with the cultured 
keratinocytes). A control for antibody specificity is shown 
in Fig. 4 b, where an immunoprecipitation/kinase reaction 
was performed in parallel with EGF receptor antibody. Au- 
tophosphorylation of the EGF receptor is readily seen in im- 
munoprecipitated receptors from cultured human keratino- 
cytes (lane G). In contrast, no phosphorylated products were 
seen in the size range of the EGF receptor (170 kD) or the 
IGF-I receptor B subunit (95 kD) in psoriatic tissue samples. 
The lower molecular mass phosphorylated products (69-46 
kD)  in  Fig.  4  a  and  b are  probably keratins and  are  not 
specifically precipitated by either antibody. 
The increased kinase activity of IGF-I receptors is consis- 
tent with the immunohistochemical  finding of increased ex- 
pression of IGFoI receptors in psoriatic epidermis and further 
indicates that these receptors are both biologically functional 
and activated in vivo. Even with the apparent increase in IGF-I 
receptor expression in lesional psoriatic epidermis, it should 
be noted that the immunohistochemical  findings indicate that 
there is a much more restricted expression of the IGFoI receptor 
in normal or psoriatic skin compared with expression of the 
EGF receptor, which is present throughout the stratum mal- 
pighii in psoriatic epidermis (9, 14, 15). This suggested that 
expression of the IGF-I receptor and the EGF receptor might 
be regulated by different biochemical pathways  in cultured 
keratinocytes or in epidermal tissue. 
Differential Modulation of lGF-I Receptor and EGF Receptor 
Expression in Human Keratinocytes.  Expression of IGF-I and 
EGF receptors was examined in cultured human keratino- 
cytes to better understand potential similarities or differences 
in regulation of these growth factor receptor systems. Fig. 
5 shows binding of 12sI-IGF-I or 12SI-EGF over a range of 
ligand concentrations to keratinocyte monolayers maintained 
in serum-flee MCDB 153 medium with and without added 
exogenous growth factors. This figure also displays a Scatchard 
transformation of the binding data. Keratinocytes maintained 
in growth factor-supplemented medium (KGM)  expressed 
approximately twice as many EGF receptors as cells main- 
tained for 24 h in unsupplemented basal medium (KBM). 
We have previously determined that IGF-I or supraphysio- 
logical concentrations of insulin (present in KGM) can trans- 
modulate EGF receptor expression on human keratinocytes 
to the same degree as shown in this experiment (9).  Thus, 
presumably the insulin component in KGM causes increased 
EGF receptor expression under these experimental conditions. 
In contrast, expression of the IGF-I receptor was not affected 
by growth factor supplementation of basal medium over a 
24-h period (Fig. 5). These data suggest that the IGF-I receptor 
might be less sensitive than the EGF receptor to transmodu- 
lation by unrelated growth factors.  Note that the binding 
curve for IGF-I can be resolved into high and low affinity 
receptor components. The high affinity  binding certainly 
represents binding of IGF-I to its receptor,  but it is possible 
that all or part of the low affinity component could be binding 
of 12sI-IGF-I to the insulin or IGF-II receptors.  Based solely 
on the high affinity receptor component, it appears that human 
keratinocytes have fewer IGF-I receptors than EGF receptors 
under identical culture conditions. If low affinity  receptor 
sites of IGF-I are considered, then keratinocytes grown in 
KGM would express approximately equal numbers of IGF-I 
and EGF receptors. 
A number of pharmacological agents have significant effects 
on binding of EGF to its receptor,  either through effects on 
cell surface receptor number or through an altered binding 
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Figure 6.  PMA treatment of keratinocyte monolayers has opposite effects 
on 12H-EGF and lzsI-IGF-I binding.  Keratinocytes in KBM were treated 
for 0-22 h with PMA (filled circles) or the inactive phorbol analogue 4c~- 
PMA (open circles). Solid lines indicate 12sI-IGF-I binding, while the dashed 
lines denote I~I-EGF binding.  Control binding was performed  on cells 
treated  with KBM containing solvent alone. 
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Figure 5.  Growth factor supplementation increases EGF receptor binding 
sites on cultured keratinocytes, but does not affect IGF-I receptor binding. 
Scatchard  analysis was  performed  with  12SI-EGF (top)  and  lzsI-IGF-I 
(bottom)  for keratinocytes grown in KGM and then transferred  to KBM 
(filled circles) or KGM (open circles) for 24 h before the assay. The insets 
in each panel are plots of the concentration  of ligand added versus specific 
binding of the ligand. 
affinity of the receptor for EGF. Given differences in the tissue 
distribution of IGF-I and EGF receptors in human epidermis, 
we sought to compare effects of potent pharmacological agents 
on expression of IGF-I and EGF receptors. Activation of pro- 
tein kinase C (PKC) by PMA rapidly decreases EGF binding 
to keratinocytes by altering EGF receptor  binding affinity (22). 
In the experiment shown in Fig. 6, binding of 12sI-IGF-I or 
125I-EGF to keratinocyte monolayers was determined after 
treatment with PMA for times up to 22 h. As a control for 
non-specific effects of phorbol compounds that are unrelated 
to PKC activation, binding  has been compared with treat- 
ment with 4ot-PMA, an inactive isomer of PMA. As expected, 
treatment of keratinocytes with PMA produced a rapid de- 
crease in x2SI-EGF binding, which was maximally depressed 
at 22 h of treatment. In contrast, opposite effects on binding 
of t2sI-IGF-I were produced by PMA treatment,  with in- 
o 
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Figure 7.  Scatchard analysis of the effects of PMA and Ca  2+/A23187 
on EGF receptor binding to cultured human keratinocytes. Keratinocytes 
were treated for 24 h with KGM alone (open circles) or containing  10 ng/ml 
PMA (filled circles) or 1.15 mM CaCI~/0.1  #M A23187 (open triangles). 
The inset is a plot of EGF concentration  added versus specific binding 
of the ligand. 
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Treatment  of keratinocytes over this period with 4ot-PMA 
produced  no  significant  change  in  I~SI-EGF or  tzsI-IGF-I 
binding. To determine whether these changes in ligand binding  25 o 
were due to alterations of receptor number or binding affinity, 
binding of these ligands to PMA-treated cells was examined 
over a range of ligand concentrations, and binding data were  Q3  20 0 
transformed to a Scatchard plot. PMA treatment  decreased 
EGF receptor binding  affinity from Kd ~0.4  to ~10  nM,  o  150 
with no apparent change in receptor number (Fig. 7). In con-  o 
trast,  PMA treatment  increased the affinity of high affinity 
t2sI-IGF-I  binding  sites  from Ka ,'o2 to "'0.6  nM (Fig.  8)  ~  l oo I 
with  no  significant  alteration  of  low  affinity  lzsI-IGF-I 
binding  sites  (data not  shown). 
As PKC,  as well as a number of other enzymes, can be  50 
activated by increased intraceUular  calcium ions, keratinocytes 
were treated with increased extracellular calcium (1.15 mM) 
or ionophore A23187 with and without increased extracel-  0 
O  lular calcium. The effect of these treatments was then mea- 
sured on binding of 12sI-IGF-I and 125I-EGF to keratinocyte 
monolayers (Fig. 9). Treatment of keratinocytes with increased 
extracellular calcium and with ionophore A23187 produced 
a time-dependent decrease in EGF binding, though the overall 
effect was not as large as that produced by PMA treatment. 
In contrast, a time-dependent increase in 12sI-IGF-I binding 
was produced by all treatments,  though ionophore A23187 
with increased extracellular calcium produced the largest in- 
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Figure 9.  Calcium and/or calcium ionophore treatment of keratinocyte 
monolayers has opposite effects on 12SI-EGF and 12sI-IGF-I  binding.  Ker- 
atinocytes in KBM were treated for 0-22 h with 1.15 mM CaC12 (filled 
circles), 0.1/~M A23187 (open circles), or both (open triangles).  Solid lines 
indicate t~I-IGF-I binding while the dashed lines denote 12SI-EGF  binding. 
Control binding was performed  on cells treated  with KBM containing 
solvent alone. 
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Figure 8.  Scatchard  analysis of the effects  of PMA, Ca  2§  and 
CaZ+/ionomycin on high affinity IGF-I receptor binding to cultured 
human keratinocytes. Keratinocytes  were treated for 24 h with KBM alone 
(open circles, solid line) or containing 10 ng/ml PMA (filled triangles,  dotted 
line)  or 1.15 mM CaC12 with either 0.1 #M A23187 (filled circles, long- 
dashed line) or 1/zM ionomycin (open triangles,  short-dashed line).  The inset 
is a plot of IGF-I concentration added versus specific  binding of the ligand. 
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crease. Scatchard analysis of the ionophore A23187 effect on 
EGF and IGFq binding (Figs.  7 and 8) showed that the de- 
creased EGF binding was largely a function of reduced receptor 
number,  whereas the increased IGF binding was produced 
by an increased affinity of high affinity binding sites. Increased 
affinity of high  affinity IGF-I receptors was also produced 
by treatment of keratinocyte monolayers with ionomycin in 
the presence of increased (1.15 mM) extracellular calcium. 
Ionomycin is an ionophore with higher selectivity for intra- 
cellular calcium transport than A23187 (23), suggesting that 
the effect of A23187 on IGF-I receptor expression is medi- 
ated through increased calcium transport and not that of an- 
other divalent cation. 
Discussion 
IGF-I,  which mediates the growth-promoting  effects of 
growth hormone,  is itself an important  hormone in deter- 
mining structure and function of adult tissues (1). While the 
primary function of IGF-I is to regulate growth-related cel- 
lular metabolism,  it could also have effects on intraceUular 
hexose transport and anabolic metabolism through crossreac- 
tion with the insulin or IGF-II receptors.  IGF-I may be an 
especially important hormone for development and homeo- 
stasis of adult tissues, since its plasma level increases throughout 
adolescence to a peak concentration  of *40 nM and levels 
plateau at m20 nM in adults (1).  These concentrations  are 
far above the Ka of the IGF-I receptor for IGF-I (~1  nM), but IGF-I access to tissues is restricted by serum binding pro- 
teins for IGF-I. Tissue responses to IGF-I in adults may also 
be  tightly regulated by IGF-I  receptor expression,  which 
decreases in many tissues throughout development and is at 
low levels in many adult tissues (6). Although IGF-I could 
potentially bind to insulin or IGF-II receptors in adult tissues, 
the mitogenic regulation of cellular growth is specifically medi- 
ated by the B subunit tyrosine kinase of the IGF-I receptor 
and not that of the insulin receptor (5).  In this context, it 
is interesting that little change is seen in expression of the 
IGF-I receptor in basal epidermal keratinocytes of neonatal 
vs.  adult  skin  (9).  The  IGF-I  receptor  may thus  play  an 
important  role  in  sustained  proliferation  of keratinocytes 
throughout life. 
Keratinocytes have previously been shown to possess IGF-I 
receptors functionally and biochemically equivalent to those 
in other tissues (7,  8).  IGF-I is a strong mitogen for ker- 
atinocytes in culture and its presence may be essential for in 
vitro keratinocyte proliferation;  however, IGF-I appears to 
act as a mitogen primarily in synergistic combination with 
either EGF-related (9,  13, 20) or FGF-related (13,  20) pep- 
tides.  Given  the  probable  role  of IGF-I  as  an  epidermal 
mitogen, the restriction of IGF-I receptor expression to the 
basal epidermal compartment may largely limit proliferation 
to basal keratinocytes in normal skin. In this regard, IGF-I 
receptor localization is more specific for keratinocytes with 
proliferative potential than is EGF receptor distribution, since 
EGF receptors can be detected at cell surface membranes of 
all viable epidermal layers (9, 14, 15). This suggests a poten- 
tially important difference in differentiation or developmental 
regulation of IGF-I and EGF receptor expression in human 
skin. 
There may also be important differences in biochemical 
regulation of ligand-receptor binding interactions in the EGF 
and IGF-I receptors. In situ binding of 12SI-EGF is primarily 
limited to basal epidermal keratinocytes in epidermis, even 
though suprabasal keratinocytes also express EGF receptors. 
This finding suggests that regulation of the binding avail- 
ability of existing EGF receptors may be an important deter- 
minant of receptor-ligand interactions in vivo (15). Based on 
our observations of diminished EGF binding to its receptor 
after treatment of keratinocytes with PMA, calcium, or iono- 
phores, it appears that EGF receptor-ligand binding can be 
highly modulated in a negative fashion, possibly through PKC- 
mediated threonine phosphorylation (22). Alternatively, in- 
creased cell surface EGF receptor number in cultured keratino- 
cytes can be rapidly induced by an IGF-I receptor-mediated 
transmodulation  (9).  In contrast,  the ability of the IGF-I 
receptor to bind IGF-I is not negatively affected by PMA, 
calcium, or ionophore treatment of keratinocytes. Thus, ex- 
pression of the IGF-I receptor is regulated differently from 
that of the EGF receptor in cultured keratinocytes. These data, 
combined with details of the IGF-I receptor gene promoter 
sequence (24) and the pattern of IGF-I receptor expression 
in epidermis, suggest that IGF-I receptor-ligand interactions 
in tissue may be more a function of differentiation-specific 
control of receptor expression rather than biochemical mod- 
ification of ligand binding potential. In preliminary experi- 
ments,  binding  of  12sI-IGF-I  to  epidermal  tissue  in  situ 
closely paralleled IGF-I receptor expression defined by im- 
munohistochemistry with oMR-3, fulfilling one prediction 
of this IGF-I receptor-ligand binding scheme. 
The increased expression of IGF-I receptors in suprabasal 
keratinocytes of lesional psoriatic skin could be important 
in regulating the keratinocyte hyperplasia associated with this 
disorder. The IGF-I receptor distribution dosely parallels that 
of the increased keratinocyte proliferative compartment in ac- 
tive psoriatic epidermis (21).  The potential need for IGF-I 
receptor activation to trigger keratinocyte proliferation might 
help to explain the relative confinement of keratinocyte prolifer- 
ation to basal and suprabasal epidermal layers  in psoriasis, 
despite increased expression  of TGF-cz  (25,  26)  and EGF 
receptors (14,  15) capable of ligand binding over the entire 
stratum malpighii in psoriasis. Indeed, mitogenic responsive- 
ness to IGF-I in some epithelial cell types appears to be con- 
trolled through regulation of cell surface IGF-I receptors and 
not the available ligand concentration (27). Even so, free IGF-I 
would need to be available to activate IGF-I receptors in psori- 
atic skin if this receptor system is relevant to psoriatic epidermal 
hyperplasia. A relative abundance of IGF-I might be avail- 
able to psoriatic epidermis through leaky, fenestrated capil- 
laries in the papillary dermis in this disorder (28), or by secre- 
tion of IGF-I in a paracrine fashion from dermal fibroblasts 
that overexpress platelet-derived growth factor receptors in 
active psoriatic lesions (29). There is even the possibility that 
IGF-I  could be  supplied to the epidermis in an autocrine 
fashion, since IGF-I immunoreactivity can be induced in the 
epidermis under some conditions (30). 
Our ability to detect IGF-I receptor kinase activity in psori- 
atic lesional keratinocytes in the absence of exogenously added 
IGF-I indicates that the IGF-I receptor pathway is activated 
in psoriatic epidermis. Our findings suggest a 5-20-fold in- 
crease in IGF-I receptor kinase activity in lesional psoriatic 
epidermis compared with uninvolved skin from the same in- 
dividuals. A role for participation of the IGF-I receptor-ligand 
system in the pathogenesis of psoriasis is further suggested 
from  clinical  improvement produced by  somatostatin-like 
drugs that diminish plasma IGF-I concentrations (31).  Fur- 
thermore, activation of the increased IGF-I receptors present 
in lesional psoriatic skin might increase EGF receptor expres- 
sion (a characteristic of psoriatic epidermis) via IGF-I-mediated 
transmodulation of the EGF receptor (9).  We should note, 
however, that minimal EGF receptor kinase was detected in 
normal and lesional psoriatic skin samples, consistent with 
previous observations of EGF receptor-dependent tyrosine 
phosphorylation in tissue samples (32). Since ligand-receptor 
binding, tyrosine kinase activation, and receptor downregu- 
lation are normally linked, one explanation for the abundance 
of EGF receptors and TGF-cz in psoriatic skin is that little 
in vivo ligand-receptor interaction actually occurs. 
1088  Insulin-like  Growth Factor I Receptor  Is Overexpressed  in Psoriasis While much remains to be learned about the function and 
regulation of the IGF-I receptor in human skin, our results 
suggest that the IGF-I receptor is likely to be a key hormone 
receptor that influences the growth of epidermis in normal 
and pathological states.  Since  the  independent mitogenic 
pathways stimulated by EGF and bFGF appear  to converge 
through the IGF-I receptor system, it could be an important 
target for therapy of hyperproliferative epidermal diseases. 
This work was supported in part by a General Clinical Research Center grant (M01-RR-00102) from 
the National Institutes of Health to The Rockefeller  University Hospital; by a grant from the Dana Foun- 
dation; by grants from the Skin Disease Society,  New York; by The Carl Herzog Foundation; by a Thomas 
J. Fitzpatrick Research Award from the Kao Corporation of Tokyo, Japan, to J. G. Krueger; by a 1989 
grant from the Dermatology Foundation to A. B. Gottlieb; and with general support from the Pew Trusts. 
J. F. Krane is supported by a Medical Scientist Training Program grant to The Rockefeller University- 
Coruell University Medical College. 
Address correspondence to J. G. Krueger, Laboratory  for Investigative  Dermatology,  The Rockefeller  Univer- 
sity, 1230 York Avenue, New York, NY 10021. 
Received for publication  27 September  199I  and in revised form  17January  1992. 
References 
1.  Danghaday, W.H., and P. Kotwein. 1989. Insulin-like  growth 
factors I and II. Peptide, messenger ribonucleic acid and gene 
structures, serum, and tissue  concentrations.  Endocr. Rev. 10:68. 
2.  Massague,  J., and M.P. Czech. 1982. The subunit structures 
of two distinct receptors for insulin-like growth factors I and 
II and their relationship to the insulin receptor..]. Biol. Chem. 
257:5038. 
3.  Czech,  M.P. 1989. Signal transmission by the  insulin-like 
growth factors. Cell.  59:235. 
4.  Ullrich, A., A. Gray,  A.W. Tam, T. Yang-Feng,  M. Tsubokawa, 
C. Collins, W. Henzel, T. Le Bon, S. Kathuria, E. Chen, S. 
Jacobs, U. Francke,  J. Ramachandran,  and Y. Fujita-Yamaguchi. 
1986. Insulin-like growth factor I receptor primary structure: 
comparison with insulin receptor suggests structural deter- 
minants that define functional specificity.  EMBO (Eur. Mol. 
Biol. Organ.) J.  5:2503. 
5.  Lammers, R., A. Gray,  J. Schlessinger, and A. Ullrich. 1989. 
Differential signalling potential of  insulin- and IGF-l-receptor 
cytoplasmic  domains. EMBO (Eur. Mol. Biol. Organ.)J. 8:1369. 
6.  Werner, H., M. Woloschak, M. Adamo, Z. Shen-Orr, C.T 
Roberts, Jr., and D. LeRoith. 1989. Developmental  regulation 
of the rat insulin-like  growth factor I receptor gene. Proa Natl. 
Acad. Sci. USA.  86:7451. 
7.  Misra, P., B.J. Nickoloff,  V.B. Morhenn, R.L. Hintz, and R.G. 
Rosenfeld. 1986. Characterization  of insulin-like  growth factor- 
I/somatomedin-C  receptors on human keratinocyte  monolayers. 
J.  Invest. Dermatol.  87:264. 
8.  Nickoloff,  B.J., P. Misra, V.B. Morhenn, R.L. Hintz, and R.G. 
Rosenfeld. 1988. Further characterization of the keratinocyte 
somatomedin-C/insulin-like growth factor I (SM-C/IGF-1) 
receptor and the biological responsiveness  of  cultured keratino- 
cytes to SM-C/IGF-1. Dermatologica (Basel). 177:265. 
9.  Krane,  J.F., D.P. Murphy, D.M. Carter, andJ.G. Krueger. 1991. 
Synergistic  effects  of  epidermal growth factor  (EGF) and insulin- 
like growth factor I/somatomedin C (IGF-I) on keratinocyte 
proliferation may be mediated by IGF-I transmodulation of the 
EGF receptor. J.  Invest. Dermatol.  96:419. 
10.  Pfeifle,  B., and H. Ditschuneit. 1983. Two separate receptors 
for insulin and insulin-like growth factors on arterial smooth 
muscle cells. Exp.  Clin.  Endocrinol. 81:280. 
11.  Kosenfeld, R.G., and L.A. Dollar. 1982. Characterization of 
the somatomedin-C/insutin-like  growth factor I (SM-C/IGF I) 
receptor on cultured human fibroblast monolayers:  regulation 
of receptor concentrations by SM-C/IGF I and insulin.J. Clin. 
Endocrinol. & Metah  55:434. 
12.  Pardee, A.B. 1989. G1 events and regulation of cell prolifera- 
tion. Science (Wash. DC). 246:603. 
13.  Ristow, H.-J., and TO. Messmer. 1988. Basic  fibrobhst growth 
factor and insulin-like growth factor I are strong mitogens for 
cultured mouse keratinocytes,  f  Cell. Physiol. 137:277. 
14.  Nanney, L.B., C.M.  Stoscheck, M. Magid, and L.E. King, 
Jr.  1986. Altered [l~I]epidermal growth factor binding and 
receptor distribution in psoriasis.  J. Invest. Dermatol. 86:260. 
15.  Green, M.R., andJ.R. Couchman. 1985. Differences  in human 
skin between the epidermal growth factor receptor distribu- 
tion detected by EGF binding and monoclonal antibody rec- 
ognition. J.  Invest. Dermatol. 85:239. 
16.  Kull,  F.C.,  Jr., S. Jacobs, Y.-F. Su, M.E. Svoboda,  J.J. Van Wyk, 
and P. Cuatrecassas. 1983. Monoclonal antibodies to receptors 
for insulin and somatomedin-C. J. Biol. Chem.  258:6561. 
17. Jacobs, S., S. Cook, M.E. Svoboda, and J.J. Van Wyk. 1986. 
Interaction of the monoclonal antibodies ~-IR-1 and oe-IR-3 
with  insulin  and  somatomedin-C receptors. Endocrinology. 
118:223. 
18.  Catanese, V.M., F. Grigorescu, G.L. King, and R.C. Kahn. 
1986. The human  erythrocyte insulin-like growth factor I 
receptor:  characterization  and  demonstration  of  ligand- 
stimulated autophosphorylation.J.  Clin. Endocrinol. & Metah 
62:692. 
19.  Furlanetto, R.W., J.N. DiCarlo, and C. Wisehart. 1987. The 
type II insulin-like growth factor receptor does not mediate 
deoxyribonucleic  acid synthesis in human fibroblasts.  J. Clin. 
Endocrinol. 6"Metah  64:1142. 
20.  Aaronson, S.A., J.S. Rubin,  P.W. Finch, J. Wong, C. Mar- 
1089  Krane  et al. chese, J. Falco, W.G. Taylor, and M.H. Kraus. 1990. Growth 
factor-required pathways in epithelial cell proliferation. Am. 
Rev. Resp/r. /~'s. 142:$7. 
21.  Van Scott, E.J., and T.M. Ekel. 1963. Kinetics of hyperplasia 
in psoriasis. Arch.  Dermatol. 88:373. 
22.  Davis, R.J.  1988. Independent mechanisms account for the 
regulation by protein kinase C of the epidermal growth factor 
receptor affinity and tyrosine-protein kinase activity.  J. Biol. 
Chem.  263:9462. 
23.  Liu, C., and T.E. Hermann. 1978. Characterization of iono- 
mycin as a calcium ionophore. J. Biol. Chem.  253:5982. 
24.  Werner, H., B. Stannard, M.A. Bach, D. LeRoith, and C.T. 
Roberts. 1990. Cloning and characterization of the proximal 
promoter region of the rat insulin-like  growth factor I (IGF-I) 
receptor gene. Biochem. Biophys. Res. Commun.  169:1021. 
25.  Gottlieb, A.B., C.K. Chang, D.N. Posnett, B. Fanelli, andJ.P. 
Tam. 1988. Detection of transforming growth factor c/in 
normal, malignant, and hyperproliferative  human keratinocytes. 
J. Exl~ Med. 167:670. 
26.  Elder, J.T., G.J. Fisher, P.B. Lindquist, G.L. Bennett, M.R. 
Pittelkow, K.J. Coffey,  Jr., L. Ellingsworth, R. Derynck, and 
J.J. Voorhees. 1989. Overexpression of transforming growth 
factor c~ in psoriatic epidermis. Science (Wash. DC).  243:811. 
27.  Stewart, A.J., M.D. Johnson, F.E.B. May, and B.R. Westley. 
1990. Role of  insulin-like  growth factors and the type I insulin- 
like growth factor receptor in the estrogen-stimulated  prolifer- 
ation of human breast cancer cells.J. Biol. Chem. 265:21172. 
28.  Braverman, I.M.,  and A. Yen. 1977. Ultrastructure  of the 
human dermal microcirculation: II. The capillary  loops of the 
dermal papillae. J. Invest. Dermatol. 68:44. 
29.  Krane, J.F., D.P. Murphy, A.B. Gottlieb, D.M. Carter, C.E. 
Hart, and J.G. Krueger. 1991. Increased dermal expression of 
platelet-derived growth factor receptors in growth-activated 
skin wounds and psoriasis.  J. Invest. Dermatol. 96:983. 
30.  Hansson, H.-A., R. Jonsson, and K. Petruson. 1988. Tran- 
siently increased  insulin-like  growth factor I immunoreactivity 
in UVB-irradiated mouse skin. J. Invest. Dermatol. 91:328. 
31.  Camisa, C.  1989. Somatostatin and a long-acting analogue, 
octreotide acetate. Relevance  to dermatology. Arch. Dermatol. 
125:407. 
32.  Gentleman, S.,  T.A. Martensen, J.J.  Digiovanna, and G.J. 
Chader. 1984. Protein tyrosine kinase  and protein phosphotyro- 
sine phosphatase in normal and psoriatic skin. Biochim. Bio- 
phys. Acta.  798:53. 
1090  Insulin-like  Growth Factor I Receptor Is Overexpressed in Psoriasis 